Treatment-related cardiotoxicity in survivors of childhood cancer (Q38156036)

29 August 2017

title

Treatment-related cardiotoxicity in survivors of childhood cancer (English)

1 reference

29 August 2017

1 reference

1

Steven E Lipshultz

1 reference

29 August 2017

Thomas R Cochran

2

1 reference

29 August 2017

Vivian I Franco

series ordinal

3

1 reference

29 August 2017

Tracie L Miller

series ordinal

4

1 reference

29 August 2017

language of work or name

English

0 references

publication date

29 October 2013

1 reference

Nature Reviews Clinical Oncology

29 August 2017

published in

1 reference

29 August 2017

volume

10

1 reference

29 August 2017

issue

12

1 reference

29 August 2017

page(s)

697-710

1 reference

Long-term survivors of childhood cancers in the United States

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Chronic health conditions in adult survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Antineoplastic chemotherapy induced QTc prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Doxorubicin-induced second degree and complete atrioventricular block

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Add-on-therapy with bevacizumab in children and adolescents with poor prognosis non-CNS solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Radiation-associated cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Radiation-associated cardiovascular disease: manifestations and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Cardiotoxicity of cancer chemotherapy: implications for children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Anthracycline-induced cardiotoxicity in children and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Anthracycline-associated cardiotoxicity in survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Predictors of inactive lifestyle among adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Characteristics and determinants of adiposity in pediatric cancer survivors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Predicting obesity in young adulthood from childhood and parental obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Cardiovascular risk factors in adult survivors of pediatric cancer--a report from the childhood cancer survivor study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Ethnic group differences in cardiometabolic disease risk factors independent of body mass index among American youth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Body mass index in long-term adult survivors of childhood cancer: a report of the Childhood Cancer Survivor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Dietary quality, caloric intake, and adiposity of childhood cancer survivors and their siblings: an analysis from the cardiac risk factors in childhood cancer survivors study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: prevalence and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Availability of smoking prevention and cessation services for childhood cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Predictors of smoking initiation and cessation among childhood cancer survivors: a report from the childhood cancer survivor study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Health behaviours in childhood cancer survivors: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Long-term smoking cessation outcomes among childhood cancer survivors in the Partnership for Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Does anthracycline administration by infusion in children affect late cardiotoxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Survival of cancer patients on therapy with coenzyme Q10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Preventing organ-specific chemotherapy toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Mitoxantrone: a new anticancer drug with significant clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Screening for Coronary Artery Disease After Mediastinal Irradiation for Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Long-term cause-specific mortality among survivors of childhood cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Cardiotoxicity after childhood cancer: beginning with the end in mind

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

QT dispersion correlates with systolic rather than diastolic parameters in patients receiving anthracycline treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Tyrosine kinases as targets for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Noninvasive Evaluation of Late Anthracycline Cardiac Toxicity in Childhood Cancer Survivors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Doxorubicin clearance in the obese

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

High risk of symptomatic cardiac events in childhood cancer survivors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Exercise capacity in long-term survivors of pediatric cancer: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

The prevalence of overweight and obesity in pediatric survivors of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Cardiovascular trials in long-term survivors of childhood cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Topoisomerase II Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxicity and Prevention by Dexrazoxane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Cardioprotective interventions for cancer patients receiving anthracyclines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Wise up: do not do it without protection!

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Antioxidant and co-antioxidant activity of vitamin C. The effect of vitamin C, either alone or in the presence of vitamin E or a water-soluble vitamin E analogue, upon the peroxidation of aqueous multilamellar phospholipid liposomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Ascorbic acid and adriamycin toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Increasing exercise in long-term survivors of pediatric cancer and their siblings: should treatment be a family affair?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.195

Letter: Prevention by coenzyme Q10 (NSC-140865) of the inhibition by adriamycin (NSC-123127) of coenzyme Q10 enzymes

31 March 2020

1 reference

12 December 2020

Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group

1 reference

12 December 2020

Monitoring for anthracycline cardiotoxicity.

1 reference

12 December 2020

Cardiac effects of dexamethasone in very low birth weight infants.

1 reference

12 December 2020

Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane

1 reference

12 December 2020

Effect of vitamin E against adriamycin-induced toxicity in rabbits

1 reference

12 December 2020

ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 199

1 reference

12 December 2020

Cigarette smoking among adults and trends in smoking cessation - United States, 2008

1 reference

12 December 2020

Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries

1 reference

12 December 2020

Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10

1 reference

12 December 2020

Beta-blockade in adriamycin-induced cardiomyopathy

1 reference

12 December 2020

Vitamin A preserves the cytotoxic activity of adriamycin while counteracting its peroxidative effects in human leukemic cells in vitro

1 reference

12 December 2020

10.1038/NRCLINONC.2013.195

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1030852499

0 references

1 reference